China’s iKang Healthcare Group Inc. rose to a seven-month high after a competitor’s parent raised its offering price, fueling a bidding war between two groups that want to delist it from U.S. exchanges and sell the shares back home.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
